Chelator-Free 99 m Tc-Labeled Yttrium Oxide Nanoparticles for Dose-Dependent Early Biodistribution Tracking in Mice
Molecular Pharmaceutics · 05.01.2026 · 23 (1) · 477-486
DOI: 10.1021/acs.molpharmaceut.5c01360 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 27.11.2025. Verfasst von Yujing Du und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China. Hauptthemen laut MEDLINE: Technetium, Nanoparticles, Yttrium. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Capital Medical University.
Abstract (Originalsprache)
Yttrium oxide (Y2O3), as a rare-earth oxide nanoparticle, has potential toxicity that remains unresolved. By bridging the gap between nanomaterial development and safety assessment, this work aimed to evaluate the biodistribution of Y2O3 using a novel radiolabeling approach with technetium-99m (99mTc) for real-time tracking. Different concentrations (0.4, 4, and 8 mg/mL) of Y2O3 were used for 99mTc labeling and were intravenously administered to mice. In vivo organ biodistribution was measured via dynamic planar imaging and micro single-photon emission computed tomography/computed tomography (micro-SPECT/CT). Biodistribution and inductively coupled plasma mass spectrometry (ICP-MS) were conducted to quantitative tissue uptake of 99mTc-Y2O3, and hematoxylin-eosin (H&E) staining were performed for histopathological evaluation. Different concentrations of 99mTc-Y2O3 were successfully synthesized with a high radiochemical purity and stability. In vivo imaging revealed different distribution patterns with 0.4, 4, and 8 mg/mL of 99mTc-Y2O3. Low-dose 99mTc-Y2O3 nanoparticles rapidly cleared from pulmonary circulation, shifting to predominant hepatic-splenic accumulation. In contrast, medium and high doses demonstrated prolonged lung retention with partial redistribution to the spleen and liver. These biodistribution patterns were validated by ICP-MS, which showed a strong correlation with the 99mTc-Y2O3 tracking. Histopathology revealed dose-related alveolar wall thickening and splenic white pulp expansion. This study demonstrated that 99mTc-Y2O3 could be a robust tool for nanoparticle in vivo tracking, providing the organ distribution information for long-term toxicity studies and chronic exposure effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China.
- Institute of Nuclear Energy and New Energy System Materials, School of Materials Sciences and Engineering, University of Science and Technology Beijing, Beijing 100083, China.
- Department of Nuclear Medicine, Peking University First Hospital, Beijing 100034, China.
ORCID-Profile: Xiaona Ren, Min-Fu Yang
Förderung
- Capital Medical University
Zitieren
APA
Du, Y., Ren, X., Wang, Y., Xu, Y., Duan, S., Fan, Y., Zhang, J., & Yang, M. F. (2026). Chelator-Free 99 m Tc-Labeled Yttrium Oxide Nanoparticles for Dose-Dependent Early Biodistribution Tracking in Mice. Molecular Pharmaceutics, 23(1), 477-486. https://doi.org/10.1021/acs.molpharmaceut.5c01360
Vancouver
Du Y, Ren X, Wang Y, Xu Y, Duan S, Fan Y, et al. Chelator-Free 99 m Tc-Labeled Yttrium Oxide Nanoparticles for Dose-Dependent Early Biodistribution Tracking in Mice. Molecular Pharmaceutics. 2026;23(1):477-486. doi:10.1021/acs.molpharmaceut.5c01360
BibTeX
@article{Du2026,
author = {Du, Yujing and Ren, Xiaona and Wang, Yao and Xu, Yang and Duan, Shida and Fan, Yan and Zhang, Jianhua and Yang, Min-Fu},
title = {Chelator-Free 99 m Tc-Labeled Yttrium Oxide Nanoparticles for Dose-Dependent Early Biodistribution Tracking in Mice},
journal = {Molecular Pharmaceutics},
year = {2026},
volume = {23},
number = {1},
pages = {477--486},
doi = {10.1021/acs.molpharmaceut.5c01360}
}
EUVIMED